Journal Reviews
Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases
This is a retrospective study of patients with ocular surface inflammatory diseases (OSIDs) treated with IKERVIS in a single centre between 2016 to 2019 with at least six months follow-up. Clinical outcome was defined as successful (resolved or stable disease),...
Management of ocular surface disease
This is a retrospective study of patients with ocular surface disease (OSIDs) treated with IKERVIS in a single centre between 2016 to 2019 with at least six months follow-up. Clinical outcome was defined as successful (resolved or stable disease), active...
Human leucocyte antigen association of patients with Stevens-Johnson syndrome in Han Chinese
This is a retrospective study of the human leucocyte antigen (HLA) polymorphism pattern of cold medicine-induced patients with Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) (n=33) and 98 control patients recruited between 2016-2017 in Taiwan. Severe ocular complications (SOC) was...
Effect of low-dose atropine on myopia progression
A randomised study to evaluate the effects of 0.01% and 0.02% atropine eye drops (one drop once nightly to both eyes) on myopic progression, pupil diameter and accommodative amplitude in myopic patients. Four hundred myopic children were divided into three...
Diclofenac versus Bromfenac after cataract surgery
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used after cataract surgery to reduce inflammation and cystoid macular oedema (CMO). Diclofenac 0.1% is used three to five times daily for 28 days and Bromfenac 0.09% twice daily for 14 days postoperatively. The...